Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2498
    -0.0013 (-0.11%)
     
  • Bitcoin GBP

    51,193.80
    -502.04 (-0.97%)
     
  • CMC Crypto 200

    1,332.72
    -63.82 (-4.57%)
     
  • S&P 500

    5,102.45
    +54.03 (+1.07%)
     
  • DOW

    38,269.79
    +183.99 (+0.48%)
     
  • CRUDE OIL

    83.87
    +0.30 (+0.36%)
     
  • GOLD FUTURES

    2,351.80
    +9.30 (+0.40%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

GSK, Theravance lung drug Relvar wins European green light

LONDON, Sept 19 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) and Theravance (NasdaqGS: THRX - news) 's new inhaled lung drug Relvar has been recommended for approval in Europe, Britain's biggest drugmaker said on Thursday.

The green light from the European Medicines Agency follows approval for the product in May in the United States, where it is known as Breo. The medicine is inhaled through a palm-sized device called Ellipta.